Our findings provide a mechanistic rationale to test PI3Kα inhibitors in combination with drugs targeting mTORC1, MEK, or BET in treating ESCC relapsed from monotherapy. The gene discussed is DNER; the disease is esophageal squamous cell carcinoma.